Work

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

Year: 2014

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-014-0110-9

Authors: James M. Cleary, Caio Max S. Rocha Lima, Herbert I. Hurwitz, Alberto J. Montero, Catherine Franklin, Jianning Yang, Alison Graham, Todd Busman, Mack Mabry, Kyle Holen, Geoffrey I. Shapiro, Hope Uronis

Institutions: Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, University of Miami, Sylvester Comprehensive Cancer Center, Duke Medical Center, Cleveland Clinic, AbbVie (United States)

Language: English

Topic: Cell death mechanisms and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: AbbVie

OpenAlex ID: W2073638417

FWCI: 2.459

Cites: 22

Cited by: 80

Related to: 10